Part-Time
Posted on 10/3/2025
Portable oxygen concentrators for home care
No salary listed
Colorado Springs, CO, USA
Hybrid
Hybrid remote position, requiring some in-person visits.
Inogen makes and sells portable oxygen concentrators for people with chronic breathing problems like COPD. These devices pull in air from the surroundings, remove nitrogen, and deliver concentrated oxygen to the user, allowing them to move around and stay independent while receiving oxygen therapy. The product is designed to be light and easy to carry, with models available to buy or rent directly from Inogen, and through a network of distributors and home medical equipment providers. What sets Inogen apart is its direct-to-consumer approach (and rental option) that bypasses traditional durable medical equipment sellers, aiming to build direct relationships with patients. The company operates in the home medical equipment market, targeting those who need long-term oxygen therapy. Its goal is to improve patients’ quality of life by providing portable, user-friendly oxygen solutions and expanding access to oxygen therapy.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Goleta, California
Founded
2001
Help us improve and share your feedback! Did you find this helpful?
401(k) Retirement Plan
401(k) Company Match
Inogen, a medical technology company focused on respiratory products, has announced several leadership appointments to accelerate growth. Jason Richardson will become chief financial officer on 6 April 2026, succeeding Michael Bourque. Richardson joins from Baxter International, where he served as CFO of the Healthcare Systems & Technologies segment. Dominic Hulton has been appointed chief marketing officer, effective 1 April 2026. Hulton brings over 20 years of experience in medical technology, most recently serving as vice president of international marketing and sales excellence at Insulet Corporation. Corey Moritz joined as vice president of US business to business sales on 9 March 2026, bringing two decades of healthcare experience. The company reaffirmed its first quarter and full year 2026 financial outlook.
Inogen, a respiratory medical device company, reported its first full year of positive adjusted EBITDA since 2021, driven by a 4% revenue increase and cost management. The company has transformed from a single-product oxygen firm into a diversified respiratory platform covering oxygen, sleep therapy, airway clearance and digital health. The company achieved 20% unit volume growth in Q4 2025, with international revenue growing 15%. Inogen maintains a strong balance sheet with $120.9 million in cash and no debt, authorising a $30 million share repurchase programme. For 2026, Inogen projects revenue of $366 million to $373 million, with stronger growth expected in the second half following new product launches. The company targets high single-digit revenue growth and adjusted EBITDA margins of 10% or better over three to five years.
/PRNewswire/ -- On the eve of the Arab Health Exhibition, Yuwell Medical held its 2025 Global Core Partner Conference in Dubai, and announced a strategic...
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Michael Bourque as Chief Financial Officer, effective March 4, 2024. Mr. Bourque has served as Treasurer and Chief Financial Officer of Chase Corporation (formally NYSE:CCF) now owned by KKR Co. Inc. He succeeds Interim Chief Financial Officer Mike Sergesketter, who will remain in an advisory role during the transition
GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the introduction of the Rove 6™ portable oxygen concentrator in the United States with best in class 8-year expected service life.The Inogen® Rove 6™ was launched in Europe in December 2022. Having completed the necessary regulatory processes, the expected service life of the Rove 6 will be extended from 5 years to 8 years for all Rove 6 devices sold worldwide. The 8 year best-in-class expected service life has also been extended to Inogen One® G5 portable oxygen concentrators in the US.“In capital-based business models it is critical to maximize the value of the devices you invest in to enhance your returns. We are excited to now be able to extend this opportunity to Inogen’s business-to-business customers allowing them to improve the profitability of their oxygen concentrator business and strengthen the appeal of the non-delivery long-term oxygen therapy model,” said Nabil Shabshab, President and Chief Executive Officer of Inogen. “As a global market leader with a focus on delivering high quality and innovative respiratory care solutions, Inogen is well positioned to deliver the best portable oxygen concentrator for business-to-business customers, with a differentiated value proposition through a strong total cost of ownership, best-in-class quality, best after sales services, and now the best-in-class expected service life.”The Inogen® Rove 6™ is a 6-setting portable oxygen concentrator that also provides the longest battery life of any portable oxygen concentrator currently available on the market